Deutsche Bank’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Deutsche Bank’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100	Closed	-$5K	–	4888
2019 Q2	$5K	Buy	+100	New	+$4.97K	﹤0.01%	5085

Other funds holding BIB

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

CAL

Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

Deutsche Bank's BIB Position: Q3 2019 in Review

Deutsche Bank sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2019, closing a stake of 100 shares — an estimated $5K sold.

Deutsche Bank first reported a position in BIB in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 25 funds tracked by Wall St. Rank hold BIB as of Q3 2019.

Deutsche Bank reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
Deutsche Bank sold 100 ProShares Ultra NASDAQ Biotechnology shares in Q3 2019, an estimated $5K.
Deutsche Bank first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2019 and held it in 1 quarter.
Deutsche Bank's ProShares Ultra NASDAQ Biotechnology position peaked at $5K in Q2 2019.
25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2019.

Based on Deutsche Bank's 13F filing for Q3 2019, filed 14 Nov 2019.